179 related articles for article (PubMed ID: 32152679)
1. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
Arshad U; Ploylearmsaeng SA; Karlsson MO; Doroshyenko O; Langer D; Schömig E; Kunze S; Güner SA; Skripnichenko R; Ullah S; Jaehde U; Fuhr U; Jetter A; Taubert M
Cancer Chemother Pharmacol; 2020 Apr; 85(4):711-722. PubMed ID: 32152679
[TBL] [Abstract][Full Text] [Related]
2. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study.
Mueller F; Büchel B; Köberle D; Schürch S; Pfister B; Krähenbühl S; Froehlich TK; Largiader CR; Joerger M
Cancer Chemother Pharmacol; 2013 Feb; 71(2):361-70. PubMed ID: 23139054
[TBL] [Abstract][Full Text] [Related]
3. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
4. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
5. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.
Thiberville L; Compagnon P; Moore N; Bastian G; Richard MO; Hellot MF; Vincent C; Kannass MM; Dominique S; Thuillez C
Cancer Chemother Pharmacol; 1994; 35(1):64-70. PubMed ID: 7987979
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre.
Moloney M; Faulkner D; Link E; Rischin D; Solomon B; Lim AM; Zalcberg JR; Jefford M; Michael M
Cancer Chemother Pharmacol; 2018 Nov; 82(5):865-876. PubMed ID: 30178115
[TBL] [Abstract][Full Text] [Related]
7. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
9. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
10. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.
Ozaki Y; Imamaki H; Ikeda A; Oura M; Nakagawa S; Funakoshi T; Kataoka S; Nishikawa Y; Horimatsu T; Yonezawa A; Matsubara T; Yanagita M; Muto M; Watanabe N
Cancer Chemother Pharmacol; 2020 Nov; 86(5):693-699. PubMed ID: 33011861
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ
J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Fety R; Rolland F; Barberi-Heyob M; Hardouin A; Campion L; Conroy T; Merlin JL; Rivière A; Perrocheau G; Etienne MC; Milano G
Clin Cancer Res; 1998 Sep; 4(9):2039-45. PubMed ID: 9748117
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic breast cancer with continuous infusional 5 fluorouracil.
Karapetis CS; Patterson WK; Pittman KB; Kotasek D; Sage RE
Aust N Z J Med; 1999 Aug; 29(4):517-22. PubMed ID: 10868530
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
Tebbutt NC; Norman AR; Cunningham D; Allen M; Chau I; Oates J; Hill M
Br J Cancer; 2003 May; 88(10):1510-5. PubMed ID: 12771914
[TBL] [Abstract][Full Text] [Related]
15. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
Marchbanks K; Dudley MN; Posner MR; Darnowski J
Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
[TBL] [Abstract][Full Text] [Related]
17. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Palmeri S; Meli M; Danova M; Bernardo G; Leonardi V; Dastoli G; Rausa L; Russo A; Filippelli G; Palmieri G; Russo A; Della Vittoria Scarpati M; Lo Russo V; Di Lauro L; Colucci G; Bruni G; Piazzi M; Gebbia N; Spada S
J Cancer Res Clin Oncol; 1998; 124(3-4):191-8. PubMed ID: 9619746
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
Cunningham J; Bukowski RM; Budd GT; Weick JK; Purvis J
Invest New Drugs; 1984; 2(4):391-5. PubMed ID: 6334665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
